Maroteaux-Lamy syndrome, or mucopolysaccharidosis type VI (MPS VI), is an autosomal recessive inborn metabolic disorder due to deficiency of the enzyme N-acetylgalactosamine-4-sulphatase, resulting in accumulation of glycosaminoglycans in most tissues. Affected individuals have coarse skin and facial features, dysostosis multiplex, hepatosplenomegaly, corneal cloudiness, upper airway nar-
rowing with obstructive sleep apnoea and chronic middle ear effusion, valvular heart disease and cardiomyopathy. Mental function is typically not affected. Patients with severe Maroteaux-Lamy syndrome die in early adult life due to cardiopulmonary complications. The first successful bone marrow transplantation (BMT) for this disease was reported in 1984. 1 However, the main limitations of allogeneic BMT are the lack of suitable HLA-compatible donors and the complications of graft-versus-host diseases (GVHD). With the advantages of relative ease of procurement, availability for immediate use, absence of risks to the donors and reduced risk of severe GVHD, umbilical cord blood is increasingly used as an alternative source of haematopoietic stem cells for transplantation. However, due to the small number of patients, experience of using cord blood transplantation (CBT) as a source for definitive enzyme replacement therapy in MPS VI is lacking. We report the first successful sibling cord blood transplantation in a patient with MPS VI.
Patient and methods

Case report
CH was the first of two children in a non-consanguineous family, born at term by spontaneous vaginal delivery. The birth history was uneventful. He had normal growth and development in the first 2 years. He presented at 2. years of age with failure to gain height, appearance of coarse facial features, frontal bossing, funnel chest and bow legs. Urine mucopolysaccharide was elevated (91 g/mol creatinine, normal range Ͻ20). Peripheral blood leukocyte and cultured skin fibroblast N-acetylgalactosamine-4-sulphatase activity levels were markedly reduced ( Table 1) . The diagnosis of Maroteaux-Lamy syndrome was confirmed. The N-acetylgalactosamine-4-sulphatase activity levels in both parents were at the lower end of the reference interval, compatible with the carrier state (Table 1) . He was referred for consideration of a haematopoietic stem cell transplant as a mean of definitive enzyme replacement therapy. However, HLA typing of the family did not reveal any compatible donor.
During the subsequent 3 years, the clinical manifes- tations became progressively more severe. He had almost stopped growing with body height 10 cm below the third percentile. Musculo-skeletal deformities increased with pectus excavatum, fixed flexion contractures of both knees (with genu varum), elbows, wrists and the interphalangeal joints (with claw hands). He became a mouth breather with chronic nasal snoring although definite obstructive sleep apnoea was not demonstrated. He had bilateral corneal cloudiness with impaired vision. He had recurrent bilateral otitis media with chronic suppurative middle ear effusion and conductive hearing impairment; repeated bilateral myringotomy and grommet implantation was required. He had an irreducible inguinal hernia that required emergency hernia repair. Echocardiogram showed the mitral valve was thickened with abnormal deposition which resulted in mitral valve incompetence. The left ventricular function was not affected. He also had progressive hepatosplenomegaly; his liver was 6 cm and spleen 5 cm below the costal margin. His intelligence and other aspects of neurodevelopment were normal. The mother had a second pregnancy but prenatal diagnosis confirmed that the fetus was affected. Termination of pregnancy was performed. The mother lastly had a third pregnancy and the fetus was prenatally shown to be unaffected by the disease (Table 1) and was also HLA-identical with CH. The parents consented to a sibling cord blood transplant.
Cord blood transplantation
Ninety-five milliliters of cord blood was collected in 25 ml of citrate phosphate dextrose before the delivery of the placenta. The cord blood was mixed with an equal volume of 20% dimethylsulfoxide, and frozen in liquid nitrogen. Umbilical cord blood transplantation was performed when the patient was 5 years old, 8 months after the cord blood was collected. The pre-transplant preparative regimen consisted of oral busulphan (1 mg/kg every 6 h for 16 doses on days −9 to −6) and intravenous cyclophosphamide (50 mg/kg daily for 4 days on days −5 to −2). On the day of transplant (day 0), the frozen cord blood was thawed, washed with albumin 2 Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin (3 mg/kg/day from day −1) and four doses of methotrexate (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6, and 11). There was no evidence of GVHD and cyclosporin was tapered off from day 50 until day 180.
The transplant was complicated by neutropenic fever without a clinical focus of infection on day 6. He was covered with empirical broad-spectrum antimicrobials. No positive culture result was obtained and fever settled on day 25 with neutrophil recovery. However, he became pyrexial again on day 48 with cellulitis at the subcutaneous tunnel of the Hickman catheter. Blood culture grew coagulasenegative staphylococcus. Infection was cleared up after removal of the Hickman catheter and a 10-day course of vancomycin. He was discharged on day 63.
Transplant outcome
The patient is currently in good clinical condition 15 months after CBT with normal blood counts. There has been no evidence of chronic GVHD. Chimerism has been assessed 3-monthly by analysis of peripheral blood mononuclear cells for DNA variable number tandem repeats. There were persistently about 10% recipient cells throughout the year, signifying stable mixed chimerism. Peripheral blood leukocyte N-acetylgalactosamine-4-sulphatase activity levels measured on days 131 and 382, respectively, were within the reference interval ( Table 2 ). The patient returned to school 10 months after the transplant with satisfactory academic performance. Clinically, the coarseness of skin and facial features significantly reduced. Suppurative middle ear effusion has not recurred even after grommets were spontaneously extruded. Hepatosplenomegaly has resolved. His height remained static in the first 5 months after transplant but then increased by 5 cm in 10 months. He can run better now and walk for long distances. The fingers are less stiff although he still has difficulties in handwriting. The contractures of the elbow and knee joints persist and he requires regular outpatient physiotherapy and occupational therapy. The corneal opacities remain the same after transplant. Follow-up echocardiogram showed that the mitral valve is still thickened with mild mitral stenosis and incompetence.
Discussion
The available options for management of severe MPS VI are limited. Enzyme replacement therapy by BMT or direct enzyme replacement has been shown to be successful in animal models. 3, 4 Since the first report of successful BMT in a 13-year-old girl with MPS VI in 1984, 1 experience has accumulated slowly due to the small number of patients. [5] [6] [7] [8] Allogeneic BMT entails considerable risks of morbidity and mortality because of cytopenia and GVHD. In nonmalignant diseases such as mucopolysaccharidosis, GVHD has no beneficial effect and should be avoided. CD34-selected peripheral blood stem cell transplantation, as a measure to reduce the risk of GVHD, has resulted in rapid haematopoietic and enzymatic recovery in a 12-year-old boy with MPS VI. 9 Cord blood has the advantage of the relative immaturity of cells and immune system at birth. 10, 11 Haematopoietic progenitors from cord blood are enriched by the most primitive stem cells that have a naive phenotype. 12, 13 These properties of haematopoietic stem cells from cord blood give them a proliferative advantage together with less frequent and less severe GVHD.
Since the first CBT performed in 1988, 14 cord blood is increasingly used as a source of haematopoietic stem cells for transplantation in both malignant and non-malignant conditions. Early reports from the International Cord Blood Transplant Registry on 44 CBT patients included one patient with Hurler disease and one with Hunter disease. 15 The two largest patient series that have been analyzed in detail were collected by the Placental Blood Program at the New York Blood Center 16 Normal marrow function has been successfully restored and a normal level of enzyme activity maintained for 15 months after CBT in this 5-year-old patient. The clinical response is demonstrated by the resolution of the hepatosplenomegaly, improvement of joint mobility, switching back to being a nose breather and resolution of chronic middle ear effusion. The skeletal deformities and corneal cloudiness, on the other hand, have not appeared to decrease. This differential improvement is consistent with other long-term follow-up experience in patients after BMT for MPS VI. 18 It appears that restoration of normal enzyme activity has a favourable effect on soft tissues but not on cartilage, bone and cornea which are probably irreversibly affected in utero.
A number of questions concerning CBT remain to be answered. The minimum cell dose requirement has not yet been determined. Eurocord experience has shown that patients who received less than 3.7 × 10 7 NC/kg took a significantly longer time for neutrophil and platelet engraftment, and none of the adult patients who received less than 1 × 10 7 NC/kg survived. 17 The NY-PCBP report has also shown a direct relation between NC cell dose and likelihood of successful engraftment. 16 CD34 + cell dose might also be a good predictor for engraftment. Unfortunately, standardization of CD34 + cell counts is not available for CBT. Furthermore, the theoretical risk of delayed immune reconstitution after CBT requires to be clarified and the risk of chronic GVHD remains to be answered.
In conclusion, umbilical cord blood transplantation has successfully replaced the deficient enzyme in this patient with Maroteaux-Lamy syndrome. There is marked improvement in quality of life after the transplant. Continued follow-up will be required to assess for long-term outcome.
